NextCure, Inc.
NXTC- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001661059
In the last 90 days, NextCure, Inc. insiders filed 2 open-market purchases and 1 sale; 30 institutions reported holding it in 13F filings for Q2 2026, worth $2.78M in total; no superinvestor holds it.
Q1 2026 vs. Q4 2025
How the institutions holding NextCure, Inc. changed between Q4 2025 and Q1 2026.
All holders in Q1 2026All holders in Q4 2025
| Measure | Q4 2025 | Of which not filed for Q1 2026 | Q1 2026 | Change |
|---|---|---|---|---|
| Holders | 24 | 1 | 26 | +3 |
| Shares | 1.90M | 91.9K | 2.17M | +363.8K (+20.1%) |
| Value | $26.9M | $1.30M | $23.0M | −$2.67M (−10.4%) |
1 institution that held it in Q4 2025 haven't filed for Q1 2026 yet. Not filing isn't selling, so the changes leave them out.
New holders (7)
Institutions that held NextCure, Inc. at the end of Q1 2026 but not at the end of Q4 2025.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Vanguard Capital Management LLC | 160,473 | $1.69M | 0.00% |
| Opaleye Management Inc. | 141,181 | $1.51M | 0.20% |
| Verdad Advisers, LP | 42,955 | $458.8K | 0.52% |
| Woodline Partners LP | 27,498 | $293.7K | 0.00% |
| Vanguard Fiduciary Trust Co | 16,015 | $168.5K | 0.00% |
| Citadel Advisors LLC | 15,292 | $160.9K | 0.00% |
| Citigroup Inc | 1 | $11 | 0.00% |
Sold out (4)
Institutions that held NextCure, Inc. at the end of Q4 2025 and filed for Q1 2026 without it.
| Institution | Shares, Q4 2025 | Value, Q4 2025 |
|---|---|---|
| Millennium Management LLC | 13,033 | $184.9K |
| Marshall Wace, LLP | 11,292 | $160.2K |
| Sio Capital Management, LLC | 10,940 | $155.2K |
| Bank of America Corp | 173 | $2.45K |
Not filed for Q1 2026 yet (1)
Institutions that held NextCure, Inc. at the end of Q4 2025 and haven't filed a 13F for Q1 2026. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q4 2025 | Value, Q4 2025 |
|---|---|---|
| Vanguard Group Inc | 91,910 | $1.30M |